PCAS: 1st Half 2021 earnings report
09 Settembre 2021 - 06:00PM
PCAS: 1st Half 2021 earnings report
Ecully, September 9, 2021
1st
HALF 2021
EARNINGS REPORT
PCAS (Euronext Paris: PCA), a
specialist in the development and production of complex molecules
for life sciences and innovative technologies, announces the
publication of its consolidated earnings for the first half of
2021.
in millions of
euros |
|
30 June 2020 |
|
30 June 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
105.1 |
|
106.3 |
|
|
|
|
|
|
|
|
|
|
EBITDA (*) |
|
7.2 |
|
8.0 |
|
|
|
EBITDA
margin |
|
6.9% |
|
7.5% |
|
|
|
|
|
|
|
|
|
|
Current operating
income (*) |
|
-3.0 |
|
-2.6 |
|
|
|
|
|
|
|
|
|
|
Other operating income and expenses |
|
-0.2 |
|
-0.4 |
|
|
|
|
|
|
|
|
|
|
Operating income |
|
-3.2 |
|
-3.0 |
|
|
|
|
|
|
|
|
|
|
Financial result |
|
-1.5 |
|
-0.9 |
|
|
Taxes |
|
-1.1 |
|
-1.3 |
|
|
|
|
|
|
|
|
|
|
Net result |
|
-5.8 |
|
-5.2 |
|
|
(*) of which research tax credit (CIR): 2.2 M€ in 2019 and 2.1 M€
in 2020 |
|
|
Results
The PCAS Group generated consolidated net sales
of €106.3 million as of June 30, 2021, representing
an increase of 1.1% compared to the same period in the previous
financial year (+3.1% at a constant exchange rate).
EBITDA amounted to €8.0 million
(€9.9 million at constant exchange rate) at June 30, 2021
versus €7.2 million at June 30, 2020.
Current operating income amounted to
-€2.6 million (-€0.7 million at constant exchange rate)
as of June 30, 2021, compared to -€3.0 million at
June 30, 2020.
Net income amounted to -€5.2 million in the
first half of 2021 versus -€5.8 million at
June 30, 2020.
Outlook
As mentioned in our previous press releases
since end-March 2020, the global coronavirus health crisis is
changing by the day, with persistent uncertainty surrounding its
duration, extent and impacts on corporate production lines as well
as consumption in general.
The potential impacts in the medium term remain
difficult to anticipate. This crisis still calls for cautious
measures. Due to the exceptional circumstances, the Group has
suspended its financial targets and strategic business objectives
until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE:
Q3 2021 net sales, on November 4, 2021.
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 10% of net sales earmarked for R&D and
a large international footprint, PCAS is the preferred industrial
partner for major market-leading global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in cutting-edge segments. PCAS generated net
sales of €194.1 million in 2020 and employs nearly
1,100 people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
NewCap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
Communication and Investor Relations |
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
Grafico Azioni PCAS (EU:PCA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni PCAS (EU:PCA)
Storico
Da Mar 2023 a Mar 2024